Shopping Cart
Remove All
Your shopping cart is currently empty
Garivulimab
(Synonyms: BGB-A333) Copy Product Info
🥰Excellent
Synonyms: BGB-A333
Catalog No. T77020 Copy Product Info
🥰Excellent
Garivulimab (BGB-A333) is a humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1). By specifically binding to PD-L1 on the surface of tumor or immune cells, it effectively blocks its interaction with the PD-1 receptor on T cells. This blockade reverses T-cell inactivation (exhaustion), promotes T-cell expansion and activation, and inhibits CD8+ T-cell apoptosis. By restoring the immune system's ability to recognize and eliminate PD-L1-expressing tumors, Garivulimab demonstrates significant anti-tumor potential in research involving various advanced solid tumors.
Cas No. 2342597-81-1
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $415 | - | In Stock | |
| 5 mg | $1,250 | - | In Stock | |
| 10 mg | $1,990 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.7% (SDS-PAGE); 98.5% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Garivulimab (BGB-A333) is a humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1). By specifically binding to PD-L1 on the surface of tumor or immune cells, it effectively blocks its interaction with the PD-1 receptor on T cells. This blockade reverses T-cell inactivation (exhaustion), promotes T-cell expansion and activation, and inhibits CD8+ T-cell apoptosis. By restoring the immune system's ability to recognize and eliminate PD-L1-expressing tumors, Garivulimab demonstrates significant anti-tumor potential in research involving various advanced solid tumors. |
| Synonyms | BGB-A333 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | PD-1/PD-L1 |
| Cas No. | 2342597-81-1 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Garivulimab chemical structure
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.